This Article Full Text (OnlineFirst PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Patterson, M. C. Articles by Wraith, J. E. PubMed PubMed Citation Articles by Patterson, M. C. Articles by Wraith, J. E. Social Bookmarking                         What's this?

Long-Term Miglustat Therapy in Children With Niemann-Pick Disease Type C

¹ Department of Neurology, Mayo Clinic, Rochester, Minnesota
² Department of Neurology, Columbia University, New York
³ Willink Biochemical Genetics Unit, Royal Manchester Children’s Hospital, Manchester, United Kingdom
⁴ Department of Optometry and Vision Sciences, University of Melbourne, Victoria, Australia
⁵ Actelion Pharmaceuticals Ltd, Allschwil, Switzerland

^* To whom correspondence should be addressed. E-mail: patterson.marc{at}mayo.edu.

	Abstract

Niemann-Pick disease type C is a rare, genetic disease associated with impaired intracellular lipid trafficking and progressive neurological symptoms. Miglustat slowed disease progression in a 12-month randomized trial in juveniles and adults with Niemann-Pick disease type C, and in a parallel, noncontrolled study in affected children. Here, the authors report the open-label extension to the pediatric study. Patients aged 4 to 12 years received open-label miglustat (dose adjusted for body surface area) for an initial 12 months, during a further 12-month extension, and a long-term, continued extension phase. Efficacy assessments included horizontal saccadic eye movement, swallowing, and ambulation. Ten children completed 24 months' treatment. Horizontal saccadic eye movement, ambulation, and swallowing were stabilized at 24 months. Analysis of key parameters of disease progression showed disease stability in 8 of 10 patients (80%). Miglustat stabilized neurological disease progression in pediatric patients with Niemann-Pick disease type C, with comparable safety and tolerability to that observed in adults and juveniles.

First published on October 12, 2009
Journal of Child Neurology 2009, doi:10.1177/0883073809344222


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?